Share Name Share Symbol Market Type Share ISIN Share Description
Futura Medical Plc LSE:FUM London Ordinary Share GB0033278473 ORD 0.2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -1.50p -4.84% 29.50p 29.00p 30.00p 34.00p 29.50p 31.00p 902,205 15:30:20
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -7.2 -4.5 - 60

Futura Medical Share Discussion Threads

Showing 16876 to 16898 of 17675 messages
Chat Pages: Latest  683  682  681  680  679  678  677  676  675  674  673  672  Older
DateSubjectAuthorDiscuss
20/6/2019
08:45
From the Liberum report. "Under the Highly Successful scenario, we believe Futura is worth £1.40 per share, almost 8x its current value." Let's hope for that outcome.Meanwhile I expect a significant advance towards their current risk adjusted 60p share price. Also worth bearing in mind Liberum's sales forecasts are very conservative .
j777j
19/6/2019
16:13
mike whatever you paid I think you'll get your money back.Too many false dawns in this stock, and too little institutional presence but it looks like finally it's coming together.I think Liberum are now supporting it.At least we know what we're aiming for and we'll know by end of Dec we'll have conclusive results.Seems LO still selling - 175K sale lunchtime.
wantage
19/6/2019
14:18
if only CSD500 had had regular progress RNSs, like Med is now having, I wouldn't be sitting on a thumping loss on FUM like I am
mikethebike4
19/6/2019
12:18
I do rather like this sort of confidence from the Broker The broker added that the Phase 3 trial for MED2002 was “low-risk̶1; as the study currently had 20 realistic outcomes, only one of which would mean the treatment could not be launched commercially. As a result, Liberum said Futura’s current share price was a “very attractive entry-point” with even its risk-adjusted valuation pointing to upside in the shares of over 100%.
ragnarr
19/6/2019
11:20
https://www.proactiveinvestors.co.uk/companies/news/219194/futura-medical-looking-ahead-to-completion-of-key-phase-iii-ed-trial-219194.html ???
horneblower
19/6/2019
11:20
J777J I think you could be right. The main focus is obviously on MED2005 but there is definitely news due at some point re TPR100 TPR100 - topical non-steroidal anti-inflammatory for the pain and inflammation associated with sprains, strains and bruises and soft tissue rheumatism In July 2018, Thornton & Ross, a subsidiary of STADA AG, Futura's UK commercialisation partner for TPR100, filed a marketing authorisation application for the product with the UK Medicines and Healthcare products Regulatory Agency (MHRA). In February 2019, the MHRA responded with some questions requiring some additional laboratory studies which are in the process of being conducted in order to address the MHRA's questions and allow the submission to progress and complete the review process. Futura has ongoing commercial discussions with several potential distribution partners for territories outside of the UK. Finalisation of such regional licensing deals is expected to be after UK regulatory approval.
ragnarr
19/6/2019
10:48
Ken James sounds extremely chipper. Still in ongoing commercial negotiations. My hunch remains a deal maybe closer than many think.
j777j
19/6/2019
10:33
Proactive Investor Interview: Sorry - I am struggling to upload the link here.
alchemist1010
19/6/2019
09:24
Pleased to see recruitment completed on time and on budget, well done FUM.
rrr
19/6/2019
09:18
Should hopefully see a nice steady rise to maybe 35/40 over the coming months and assuming data is good at the end of the year the sky is the limit then
ragnarr
19/6/2019
07:49
Ties in nicely with this "Futura Medical PLC’s (LON:FUM) data from a Phase 3 trial of its MED2005 erectile dysfunction treatment could drive the share price up over 500% according to analysts at Liberum Capital, who on Monday initiated the stock with a ‘buy’ rating and 60p target price. In its initiation note, the ‘house’ broker for the AIM-listed pharma firm said they expected positive data from the Phase 3 trial for MED2002, which is expected to be delivered by December this year." So maybe November we will know the outcome.
j777j
19/6/2019
07:14
James Barder, Chief Executive Officer, Futura Medical said: "We are extremely pleased to complete recruitment of over 1,000 patients for the first European Phase 3 study, "FM57", of MED2005, within our expected timelines and budget and I would like to thank all parties involved in reaching this important milestone. The Company's focus is now on the Phase 3 data read-out at the end of the year, which we hope will significantly clinically de-risk MED2005, and help provide commercial partners with greater certainty around the potential opportunity it presents." The potential market for this product is large with potential peak sales in excess of US $1 billion. If MED2005 is approved, there is an estimated $560M prescription-only market potential (sources: Decision Resources and Cello), and an estimated incremental $660M+ market potential as an over-the-counter (OTC) product, in markets where switch is possible. (source: Ipsos Mori forecasts commissioned by Futura).
j777j
18/6/2019
17:01
Good old Grannypants always knows best.
j777j
17/6/2019
14:33
As my dear old gran used to tell me "all good things come to those that wait"
ragnarr
17/6/2019
13:27
Simply need US bio fund or two onboard and the shares will rerate.
j777j
17/6/2019
12:19
Liberum's figures are ultra conservative and that simply amplifies the value here.
j777j
17/6/2019
11:56
Thanks J777J.
rrr
17/6/2019
11:47
Liberum "The multi-billion dollar market for erectile dysfunction (ED) therapies continues to be dominated by PDE-5 inhibitors, despite a slow onset of action and negative side-effects. We believe Futura’s MED2005 addresses these issues and expect positive P3 data in December. Our confidence is driven by compelling P2 data, a non-binary set of potential outcomes, and a rock-solid safety profile. With a market cap of just £50m vs a peak sales potential of c.£500m, we think the market misses this low risk potential. BUY." "Key catalyst due by Dec 2019 Unlike with most drug discovery businesses, there is not long to wait for the key catalyst, with the headline P3 data due by December. This could drive >500% upside." Yes >500% upside!! "Liberum view: Headline data from FM57 is due by the end of December 2019, which is the key catalyst for the shares. This data alone should be enough to secure a significant outlicensing agreement, but more importantly de-risk the confirmatory second P3 study." "We have not provided much detail on potential competition in the pipeline, as frankly we do not see any at this stage."
j777j
17/6/2019
11:34
Just a game of patience here, happy holding.. chart looks good though! One on the move, outdoors be under valued too (C4XD) dyor as usual
ny boy
17/6/2019
09:49
>>>martinelwick You can download the note from Research tree https://www.research-tree.com/companies/uk/pharmaceuticals/futura-medical
timbo003
17/6/2019
08:46
Hi can you provide the link.
martinelwick
17/6/2019
08:18
Liberum 60p price target fair value and 137p high end
j777j
17/6/2019
08:10
Bullish research report from Liberum today."High probability of success,low valuation......"
j777j
Chat Pages: Latest  683  682  681  680  679  678  677  676  675  674  673  672  Older
Your Recent History
LSE
FUM
Futura Med..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191021 15:04:24